Rationale: Many patients with chronic obstructive pulmonary disease (COPD) have an accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients with moderately severe disease.
Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated loss of lung function over time as compared with people of a similar age without airflow obstruction (1, 2) . This original observation by Fletcher and Peto (3) has been confirmed in subsequent studies of mild (4) and severe (5) COPD, although recent data with 3-10 years of follow-up suggest that this is not universally the case (6) (7) (8) . Tobacco smoking is the most important etiological factor, and cross-sectional and longitudinal data (4, 9) show that the rate of decline of FEV 1 is slower when people stop smoking, although the timing of smoking cessation affects the magnitude of the subsequent change in lung function decline (10, 11) .
Researchers in several studies have examined whether inhaled drugs can modify the rate of FEV 1 decline, with mixed results. An inhaled short-acting antimuscarinic drug did not change disease progression in the Lung Health Study (4) . However, a post hoc analysis of data from the UPLIFT (Understanding Potential Long-Term Impacts on Function) study of a once-daily long-acting antimuscarinic agent suggested a drug effect in patients naive to therapy and in those with moderate airflow obstruction (12, 13) . The initial studies of treatment with inhaled corticosteroids (ICSs) failed to identify any change in the rate of decline over a wide range of spirometrically defined COPD severities. However, the combination of an ICS and a long-acting b-agonist (LABA) did reduce airway inflammation in patients with moderate COPD (14) and was associated with a change in FEV 1 decline in the TORCH (Towards a Revolution in COPD Health) study (15) . More recently, in carefully selected patients with moderately severe COPD, the ICS fluticasone propionate decreased lung function decline and reduced airway inflammation in a 3-year trial (16) . Hence, there is continuing uncertainty about the impact of ICSs on this marker of disease progression.
The SUMMIT (Study to Understand Mortality and Morbidity) was a randomized, double-blind, placebocontrolled, parallel-group comparison of the ICS fluticasone furoate (FF), the LABA vilanterol (VI), and the combination of the two (FF/VI) with placebo in patients with moderate airflow limitation and either a history of or a significant risk of developing cardiovascular (CV) disease (17) . The primary endpoint of all-cause mortality did not differ between treatments (18) . However, given the size of the study and the potential for interaction between respiratory and CV diseases, the prespecified key secondary outcome was the effect of therapy on the rate of FEV 1 decline. In the present study, we examined how ICS and LABA therapies alone and in combination impact lung function decline in patients with COPD and moderate spirometric impairment, and we considered whether the factors associated with decline are similar to those seen in studies of more severe COPD where CV comorbidity was less prevalent.
Methods
Details of the study design and the analytical approach were published previously (17, 18 ). Patients were current or former smokers who had at least a 10-pack-year smoking history, were aged 40-80 years, had a post-bronchodilator FEV 1 greater than or equal to 50% and less than or equal to 70% of predicted value, had an FEV 1 /FVC ratio less than or equal to 0.70, and had a score greater than or equal to 2 on the modified Medical Research Council dyspnea scale. Patients with a current diagnosis of asthma were excluded. All patients provided written informed consent. The study was approved by local ethics committees, was conducted in accordance with good clinical practice guidelines, and is registered with www.clinicaltrials.gov (NCT01313676; study 113782).
Study Design
This was a prospective, double-blind, parallel-group, placebo-controlled, eventdriven, randomized trial conducted at 1,368 centers in 43 countries. Participants were randomly assigned through a centralized randomization service in permuted blocks to one of four treatments: placebo, FF 100 mg (GlaxoSmithKline) VI (25 mg; GlaxoSmithKline), or the combination of FF/VI (100 mg/25 mg [Relvar/Breo]; GlaxoSmithKline), administered once daily with a dry powder inhaler (Ellipta; GlaxoSmithKline). The use of all ICSs and long-acting bronchodilators was discontinued at least 48 hours before study entry. Other COPD medications such as theophylline were permitted. Patients unable to tolerate withdrawal of therapy were excluded.
In this study, the principal outcome was the rate of post-bronchodilator FEV 1 decline. At visit 1 (screening), the highest of three FEV 1 measurements was recorded before and 30 minutes after inhalation of albuterol 400 mg (19) . At visit 2 (randomization) and at visits every 3 months, post-bronchodilator measurements of FEV 1 were obtained while subjects remained on treatment. Spirometers were calibrated regularly according to the manufacturer's recommendations, and a calibration log was kept. Lung function data were reviewed centrally during the study and queried if 
Statistical Analysis
This was an event-driven study where follow-up continued until at least 1,000 deaths occurred. Because the treatment effect on the primary endpoint was not statistically significant, the statistical testing reported should be interpreted as descriptive only (18) . The effect of treatment on rate of decline in FEV 1 was a predefined secondary endpoint and was analyzed using a random coefficients model. Additional analyses described in this report were conducted post hoc to further investigate rate of decline in FEV 1 .
The rate of decline of FEV 1 was analyzed using a random coefficients model (20) allowing for covariates of age, sex, and baseline FEV 1 . The slope in each treatment arm was modeled by treatment, time, and treatment-by-time interaction terms (base model). The treatment-by-time interaction was used to assess whether the slopes were different between treatment arms. The slope was calculated from Postrandomization Day 90 to ensure that any initial short-term increase in FEV 1 did not overestimate any treatment benefit on the slope. A sensitivity analysis was performed using baseline as the first time point for response that also included patients with only a baseline value; in this analysis, we also calculated the slope from Day 90. For further details, see the supplementary appendix in the primary publication (18) .
The effects of treatment and various covariates on the rate of decline were modeled using the random coefficients model on the absolute scale (FEV 1 [ml] and FEV 1 percent predicted) as well as the relative scale (percentage change using a logarithmic transformation). The predicted values were those of Hankinson and colleagues as derived from the NHANES (National Health and Nutrition Evaluation Survey) study (21, 22) . Analyses of relative rate of decline in FEV 1 were performed on the logarithmic scale using the same model but with logarithmic FEV 1 and logarithmic baseline FEV 1 . Estimates of slopes were exponentiated and expressed as the percentage change.
To investigate the effects of a particular covariate, terms for the covariate and covariate-by-time interaction were added to the base model described above. The covariate-by-time interaction gave the effect of the covariate on the slope. The slopes were estimated for each subgroup after adjusting for the covariates in the base model. When the effect of age on the rate of decline was investigated, it was fitted as a categorical variable. To investigate whether the treatment effect was consistent for various subgroups of patients, estimates of the rate of decline by treatment were obtained from a separate model for each subgroup. A P value for the interaction of treatment by subgroup by time was obtained from a model that included this term as well as the subgroup-by-time and subgroup-by-treatment interactions in addition to the base model. The percentage of patients who experienced a change from baseline to 90 days of greater than or equal to 100 ml was summarized.
Results
A total of 16,590 subjects were randomized. Of these, 22 participants never took a study medication, and the safety population therefore consists of 16,568 patients. Data from five centers (83 patients) were excluded from the efficacy analysis because of failure to meet the standards of good clinical practice and ethical practice and were closed before the study ended. Thus, a total of 16,485 patients were included in the intention-to-treat efficacy population, of whom 1,037 died before the study ended.
The overall safety and demographic characteristics of the patients in this study were published previously in the primary report (18) . Among the patients, 75% were male, 47% were current smokers, mean body mass index (BMI) was 28 kg/m 2 , and 39% had a history of one or more COPD exacerbations in the year prior to the study. Mean reversibility as a percentage of prebronchodilator was 8.1%. Baseline respiratory therapy before randomization was similar between groups, with 33% (ranging from 33 to 34%) using ICSs and 35% (ranging from 34 to 36%) using LABAs. Full demographic information for the patients included in this analysis is presented in Table E3 in the online supplement. There were no differences in the demographic variables between the treatment arms. The distribution of the patients in the study treatment arms is shown in Figure 1 . More patients withdrew from placebo than in the active treatment arms (placebo, 29%; FF, 26%; VI, 25%; FF/VI, 23%).
Rate of Decline in FEV 1
Of the 16,485 participants, 15,457 contributed an average of seven postbronchodilator spirometric measurements (assessed every 3 mo). There were 112,159 on-treatment spirometric assessments used in the primary analysis. The average treatment exposure was 1.7 years.
The absolute and relative rates of FEV 1 decline with each therapy are presented in Table 1 . Data are also expressed as a change in post-bronchodilator FEV 1 percent predicted and are shown in Figure 2 and Tables 1 and 2 . Regardless of the way the data are expressed, patients receiving FF, either alone or with VI, had a slower rate of FEV 1 decline than those in either the placebo-or VI-alone groups. This represented an 8 ml/yr improvement in decline between FF/VI and placebo, or approximately a 20% difference (Table 1) in annual decline in FEV 1 percent predicted values between these groups. Sensitivity analyses did not change these findings (Table 2) , and the findings were also similar for those patients who withdrew from ICSs/long-acting bronchodilators prior to the study start (see Table E1 ).
Between baseline and Day 90, FEV 1 increased more in the treatment arms than in the placebo arm. Overall, 27% of placebo patients, 32% in the FF group, 35% in the VI group, and 38% of FF/VI patients achieved a 100-ml increase in postbronchodilator FEV 1 . Although FEV 1 increased in all three active arms, the rate of decline improved only in arms containing FF.
Determinants of Rate of FEV 1 Decline
The effect of the baseline variables on the overall rate of decline in lung function is shown in Table 3 . The rate of decline of FEV 1 , however expressed, was more rapid in males and in current smokers. Lower BMI values were also associated with faster lung function loss. In patients over 60 years of age, the presence of CV disease was accompanied by a more rapid decline in FEV 1 than CV risk. Lung function in patients with an FEV 1 percent predicted above 60% appeared to decline faster, regardless of whether the data were expressed as an absolute value or as a percent predicted value. However, if the decline was expressed as a relative change from the initial value, this effect of baseline FEV 1 on decline was no longer significant.
Age and self-reported exacerbation history were not associated with differences in rate of FEV 1 decline. Patients in the placebo arm who experienced exacerbations while on treatment had a faster decline in FEV 1 than did those who never had exacerbations (mean FEV 1 decline 59 ml/yr if .0.5 events/yr compared with 40 ml/yr in those without exacerbations) ( Table E2 ). The same relationship between treatment and rate of decline was seen in patients without incident exacerbations as in the overall One subject randomized to placebo in the intention-to-treat efficacy population was assigned to combined fluticasone furoate and vilanterol (FF/VI), the treatment the subject received for the majority of the study, in the safety population. 2 Excluded patients were recruited at sites that were closed owing to the result of audit findings or other information implying that the integrity of the data had been compromised. study population. The effect of treatment was consistent, regardless of the other baseline characteristics reported above (Table 4) .
Discussion
To our knowledge, SUMMIT is the largest study to date to characterize the rate of decline of lung function in COPD and its interaction with inhaled treatment. Moreover, to our knowledge, SUMMIT is the only study in which patients with symptomatic COPD and moderate airflow obstruction who either have or are at risk of developing CV disease, a major comorbidity of COPD, have been evaluated. Our data show that, when used alone or in combination with a LABA, ICSs reduce the rate of decline in lung function compared with placebo. These findings have implications for how to approach patients with COPD and how disease progression should be studied.
Previous studies have produced conflicting results about the effect of inhaled bronchodilators, and especially ICSs, on FEV 1 decline in COPD. Most studies have not revealed an effect on the rate of decline with ICSs (5, (23) (24) (25) , although the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) study of moderately severe COPD (16) and an analysis of the TORCH data showed that ICSs, whether used alone or in combination with a LABA, slowed the decline in FEV 1 (15) . In SUMMIT, the picture was clearer, with only those patients receiving the ICS showing benefit. The absolute rate of decline in FEV 1 was similar to that seen in ICS-treated patients in TORCH, although the decline in the placebo group was somewhat lower in SUMMIT, perhaps reflecting differences in patient recruitment and in rates of withdrawal and exacerbations between these studies. Our results resemble those predicted on the basis of earlier pharmacoepidemiology studies of patients not necessarily classified by FEV 1 severity (26) and those in a metaanalysis of studies of 2 years or more using ICSs without a long-acting bronchodilator, where a 7.7 ml/yr reduction in decline was seen in ICS-treated patients (27) . This is consistent with our findings of an 8 ml/yr absolute difference, or an approximate 20% reduction in mean in FEV 1 decline, over the mean of 1.7 years of follow-up. In practice, this is likely to underestimate the true impact in patients able to show a response. Recent data suggest that only about half of patients with impaired lung function in midlife have reached this point through an excess loss of lung function (28) , and it seems reasonable to speculate that it is only this subgroup that drives the signal we observed. The mechanisms underlying such an effect cannot be addressed in this article, although as noted earlier, there is evidence for an antiinflammatory effect of ICSs in patients with moderate COPD (16). Nonetheless, this positive impact on lung function decline in SUMMIT was not reflected in the mortality risk in different study arms, which was driven by CV and cancer deaths rather than those resulting from respiratory causes (18) .
Unlike the TORCH trial, monotherapy with a LABA did not affect rate of FEV 1 decline. This might be due to the drug selected, although the other clinical effects of once-daily VI, such as exacerbation prevention, are similar to those of twicedaily salmeterol (29) . Alternatively, the occurrence of fewer exacerbations in our trial may be relevant, raising the possibility that different therapies may act in different ways to modify FEV 1 decline, depending upon disease severity. Support for this idea comes from the post hoc analysis of the UPLIFT data in moderate COPD, where use of tiotropium was associated with a slower rate of FEV 1 decline (13) . In this UPLIFT population, 70% of participants used a LABA and/or ICS during the trial, whereas only one-third of our patients used these drugs before randomization. The exacerbation rate in patients with moderate COPD in the control arm of UPLIFT was 0.70 events/yr compared with the 0.35/year in placebo-treated SUMMIT patients (18) .
The covariates of rate of decline were similar to those established in the TORCH data (15) . Recently, it has been suggested that presenting lung function decline as a percentage of the initial value will overcome the apparent "horse racing" problems in data interpretation (30) . Patients with a post-bronchodilator FEV 1 of 60% predicted or more declined, on average, 11 ml/yr faster than the patients with greater impairment in lung function, in keeping with earlier observational data (7) . Normalizing for the initial FEV 1 removed this effect, suggesting that the relative change in lung function was independent of the degree of spirometric impairment. This aside, the use of relative change in FEV 1 decline produced the same results as the more traditional ways of expressing the data. Age was not a predictor of a different rate of decline, but current smoking status had a relatively large effect: Lung function in ex-smokers declined 14 ml/year more slowly than in those who continued to smoke. There was a gradient of response across the BMI categories, with the highest subgroup declining most slowly, the rates in the present study being very similar to those in the TORCH trial. This effect of BMI may explain some of the differences between studies because in SUMMIT, the mean BMI was 28 kg/m 2 compared with a lower mean BMI of 25 kg/m 2 observed in TORCH, and FEV 1 decline in the placebo group was more rapid than that observed in SUMMIT.
As noted elsewhere (15, 31) , decline in lung function was slower in women than in men, and in our trial, this was not fully corrected when the data were adjusted for body size, as was the case in the TORCH study data. Whether this reflects differences in the way COPD develops between the sexes as recently proposed (32) remains to be clarified. We saw no relationship between reported exacerbation frequency and subsequent decline in FEV 1 , as was the case in TORCH (15) . However, the impact of exacerbations resulting in a faster decline was reported in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) trial (7), as was observed in patients in the placebo arm with more exacerbations during the present study.
Inference about the interaction between treatment, exacerbations, and FEV 1 decline is difficult, but ICS use was associated with the same reduction of decline in patients who never experience exacerbations (the majority of the trial population), suggesting that this effect was not mediated by the difference in exacerbation events reported elsewhere (33) . There was no convincing interaction of therapy effects with any of these covariates, suggesting that the treatment-related changes observed were not confined to a specific subgroup.
Our study has strengths and limitations. The large population studied and the lower dropout rate than earlier studies (34, 35) allowed us to calculate a more precise estimate of the effect size of therapy that was smaller than what previous studies were powered to demonstrate. Our intention-to-treat efficacy population is not a true intentionto-treat analysis population but reports data only from patients who continued to participate in the trial, a finding common to other large intervention studies (4, 5, 13, 15, 16) . Special care was taken to obtain robust spirometric data because rate of FEV 1 decline was a prespecified outcome in SUMMIT. Our patients were receiving less background therapy that could potentially confound the outcome (12) . SUMMIT was an event-driven study with a shorter total follow-up period than those used in earlier trials. However, we analyzed the decline data using a random coefficients statistical model, which gives most weight to patients contributing most data points. These estimates of differences in the rate of decline were supported by the other analyses we report and are likely to be robust, reflecting the large number of patients contributing to the study. Recent reanalysis of data from the ISOLDE (Inhaled Steroids in Obstructive Lung Disease in Europe) study suggests that blood eosinophil counts may identify patients for whom ICSs can reduce FEV 1 decline (36) . Unfortunately, no eosinophil data were collected in the present study, so we cannot address this possibility. Finally, we recruited patients with COPD and overt or potential CV disease who might respond differently from groups where such pathology is less evident. However, the similarity in the impact of common covariates and the observed rates of decline between our data and data reported elsewhere suggests that this is not the case. Our findings have implications for the way in which the lung function progression of COPD is viewed. The positive response to ICSs, an antiinflammatory drug category, provides further evidence that drug treatment can modify the lung function decline characteristic of this condition. Although ICSs did not affect survival, the mean absolute change in FEV 1 decline in SUMMIT was close to that observed with smoking cessation in the Lung Health Study (4) and represents a reduction in the likely excess decline in FEV 1 in our patients, whose normal lung function loss would be 25-30 ml/yr (36) . This effect might be further improved if we could identify responsive patients more effectively and in whom comparable changes in lung function decline could become important over time (37) . As such, our results suggest that large numbers of patients are needed to identify a small average signal, which helps explain why earlier, smaller studies were unsuccessful, but it also suggests that adequately powered studies conducted in appropriate patient groups can identify a treatment effect in less than 3 years.
In summary, the regular use of FF, either alone or in combination with VI, appears to reduce the rate of FEV 1 decline in patients with moderate COPD and a heightened risk of CV disease. This important finding in a study whose primary mortality endpoint was negative suggests that any benefit from these drugs is likely restricted to the respiratory system. Future studies to support our observations would be welcome and will hopefully determine whether antiinflammatory therapy and/or other bronchodilator treatment can further ameliorate lung function decline in the natural history of COPD. n Definition of abbreviations: BMI = body mass index; CI = confidence interval; CV = cardiovascular; FF = fluticasone furoate; VI = vilanterol.
Interaction P values are derived from the subgroup-by-treatment-by-time term in the random coefficients model containing all four treatment arms.
Estimates of rate of decline are derived from the random coefficients model including four treatment arms using a separate model for each subgroup. "n" refers to the number of patients included in the analysis.
